Overview

Evaluation of Adhesion and Dermal Tolerability of EMSAM

Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
Examine adhesive and dermal tolerability of EMSAm 6mg/24hr and 12mg/24hr in healthy elderly and non-elderly subjects.
Phase:
Phase 4
Details
Lead Sponsor:
Somerset Pharmaceuticals
Treatments:
Selegiline